GU012: SAMURAI Trial — Combining Stereotactic Ablative Radiation and Immunotherapy for Advanced Renal Cell Carcinoma
Study Overview:
GU012 evaluates whether adding stereotactic ablative radiation therapy (SABR) to immunotherapy improves tumor control and long-term survival in patients with unresectable metastatic renal cell carcinoma (RCC) compared to immunotherapy alone.
Key Study Details:
Phase & Design: Phase II, randomized
Population: Patients with metastatic, unresected RCC receiving immunotherapy
Treatment Arms: SABR + immunotherapy vs. immunotherapy alone
Primary Objective: Improve progression-free survival
Why It Matters: Combining precise high-dose radiation with immune-based therapy may improve responses in resistant tumors.